PMID: 11341957May 9, 2001Paper

The Rossmann fold of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a nuclear docking site for antisense oligonucleotides containing a TAAAT motif

Biochimica Et Biophysica Acta
C GriffoniV Tomasi

Abstract

The subcellular localisation of oligodeoxynucleotides (ODN) is a major limitation for their use against nuclear targets. In this study we demonstrate that an antisense ODN directed against cytosolic phospholipase A(2) (cPLA2) mRNA is efficiently taken up and accumulates in the nuclei of endothelial cells (HUVEC), human monocytes and HeLa cells. Gel shift experiments and incubation of cells with oligonucleotide derivatives show that the anti-cPLA2 oligo binds a 37 kDa protein in nuclear extracts. The TAAAT sequence was identified as the major binding motif for the nuclear protein in competition experiments with mutated ODNs. Modification of the AAA triplet resulted in an ODN which failed to localise in the nucleus. Moreover, inserting a TAAAT motif into an ODN localising in the cytosol did not modify its localisation. The 37 kDa protein was purified and identified after peptide sequencing as glyceraldehyde-3-phosphate dehydrogenase (GAPDH). It was shown by confocal microscopy that GAPDH co-localises with anti-cPLA2 ODN in the nucleus and commercial GAPDH effectively binds the oligo. Competition experiments with increasing concentration of NAD(+) co-factor indicate that the GAPDH Rossmann fold is a docking site for antisense olig...Continue Reading

References

Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·J P LeonettiB Lebleu
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·L A YakubovV V Vlassov
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S L LokeL M Neckers
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·H TomuraV M Nikodem
Nov 1, 1995·Nature Medicine·R W Wagner
Apr 1, 1995·The Journal of Clinical Investigation·C BeltingerA M Gewirtz
Dec 8, 1994·Biochimica Et Biophysica Acta·M OrlandiV Tomasi
Feb 1, 1994·The Journal of Clinical Investigation·T WuJ H Shelhamer
May 9, 1994·FEBS Letters· Rykova EYuV V Vlassov
Nov 1, 1993·The Journal of Investigative Dermatology·S B NoonbergC A Hunt
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·Z Dominski, R Kole
Apr 12, 1996·Journal of Molecular Biology·M Sioud, L Jespersen
Jul 1, 1996·Genes & Development·J L Manley, R Tacke
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·S Y ChengW K Cavenee
Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·H SierakowskaR Kole
Dec 15, 1996·Experimental Cell Research·D L Spector
Jan 10, 1997·The Journal of Biological Chemistry·L A MarshallA Roshak
Apr 1, 1997·Nature Medicine·L BenimetskayaC A Stein
Jul 4, 1997·The Journal of Biological Chemistry·C C Leslie
Oct 23, 1997·Proceedings of the National Academy of Sciences of the United States of America·A SawaS H Snyder
May 9, 1998·Science·A I Lamond, W C Earnshaw
May 22, 1998·Molecular Biology of the Cell·P LorenzD L Spector
May 21, 1998·Antisense & Nucleic Acid Drug Development·L A Marshall, A K Roshak

❮ Previous
Next ❯

Citations

Mar 16, 2005·Biochemical and Biophysical Research Communications·Ilaria TommasiniOrazio Cantoni
Sep 8, 2011·Clinical and Experimental Pharmacology & Physiology·Craig NichollsJun-Ping Liu
Jul 11, 2006·Biochemistry. Biokhimii︠a︡·B P ChelobanovV V Vlasov
Oct 3, 2002·The Journal of Biological Chemistry·Elena Evguenieva-HackenbergGabriele Klug
Oct 21, 2003·Nucleosides, Nucleotides & Nucleic Acids·P P LaktionovV V Vlassov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.